1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. New York >
  6. Veracyte Acquires C2i

M&A Deal Summary

Veracyte Acquires C2i

On January 8, 2024, Veracyte acquired internet software and services company C2i for 70M USD

Acquisition Highlights
  • This is Veracyte’s 1st transaction in the Internet Software and Services sector.
  • This is Veracyte’s 3rd largest (disclosed) transaction.
  • This is Veracyte’s 3rd transaction in the United States.
  • This is Veracyte’s 1st transaction in New York.

M&A Deal Summary
Date 2024-01-08
Target C2i
Sector Internet Software and Services
Buyer(s) Veracyte
Deal Type Add-on Acquisition
Deal Value 70M USD
Advisor(s) Perella Weinberg Partners (Financial)
Meitar Liquornik Geva Leshem Tal (Legal)

Target

C2i

New York, New York, United States
C2i is a minimal residual disease (MRD) detection company that empowers researchers, physicians, and patients with ultra-sensitive whole-genome cancer detection. The company's SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using scientific breakthroughs, growing genomic and clinical databases, and sophisticated signal processing and AI, it enables high-precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. C2i is based in New York, New York.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Veracyte

South San Francisco, California, United States
Category Company
Founded 2006
Sector Life Science
Employees824
Revenue 446M USD (2024)
DESCRIPTION

Veracyte is a molecular cytology company. Veracyte seeks to use molecular cytology to improve diagnosis with the promise to help physicians and patients make more informed treatment decisions. Veracyte solution will utilize molecular biomarkers on cytology samples to characterize nodules as benign or suspicious of malignancy. Veracyte was founded in 2006 and is based in South San Francisco, California.

DEAL STATS #
Overall 4 of 4
Sector: Internet Software and Services M&A 1 of 1
Type: Add-on Acquisition M&A Deals 4 of 4
State: New York M&A 1 of 1
Country: United States M&A 3 of 3
Year: 2024 M&A 1 of 1
Size (of disclosed) 3 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-01 HalioDx

Marseille, France

HalioDx is an immuno-oncology diagnostics company providing oncologists and drug development organizations with first-in-class diagnostic products and services to guide cancer care and contribute to precision medicine. HalioDx was founded in 2015 and is based in Marseille, France.

Buy €260M
Mergr

Solution for

Product

Company

Legal